EKF Diagnostics Holdings PLC
LSE:EKF

Watchlist Manager
EKF Diagnostics Holdings PLC Logo
EKF Diagnostics Holdings PLC
LSE:EKF
Watchlist
Price: 25.7 GBX 1.98% Market Closed
Market Cap: 116.6m GBX
Have any thoughts about
EKF Diagnostics Holdings PLC?
Write Note

EKF Diagnostics Holdings PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

EKF Diagnostics Holdings PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
EKF Diagnostics Holdings PLC
LSE:EKF
Additional Paid In Capital
ÂŁ7.4m
CAGR 3-Years
233%
CAGR 5-Years
N/A
CAGR 10-Years
-22%
Smith & Nephew PLC
LSE:SN
Additional Paid In Capital
$615m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Additional Paid In Capital
$2.2B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
18%
Angle PLC
LSE:AGL
Additional Paid In Capital
ÂŁ118.4m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Additional Paid In Capital
ÂŁ180.9m
CAGR 3-Years
16%
CAGR 5-Years
22%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Additional Paid In Capital
$33.4m
CAGR 3-Years
291%
CAGR 5-Years
59%
CAGR 10-Years
N/A
No Stocks Found

EKF Diagnostics Holdings PLC
Glance View

Market Cap
116.6m GBX
Industry
Health Care

EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.

EKF Intrinsic Value
31.9 GBX
Undervaluation 19%
Intrinsic Value
Price

See Also

What is EKF Diagnostics Holdings PLC's Additional Paid In Capital?
Additional Paid In Capital
7.4m GBP

Based on the financial report for Jun 30, 2024, EKF Diagnostics Holdings PLC's Additional Paid In Capital amounts to 7.4m GBP.

What is EKF Diagnostics Holdings PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
-22%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for EKF Diagnostics Holdings PLC have been 233% over the past three years , and -22% over the past ten years .

Back to Top